VKORC1 and CYP2C9 Genetic Variants Coumarin Response in the Mestizo-Mexican Population

Document Type : Original Article

Authors

1 Cardiothoracic Surgeon, Cardiovascular Department, CMN 20 de Noviembre, ISSSTE. México City.

2 Science Research Doctor, Biomedical Research Department, CMN 20 de Noviembre ISSSTE, México City.

3 Pharmacobiological Chemistryc, Hormons Laboratory, CMN 20 de Noviembre ISSSTE, México City.

Abstract

Introduction: Polymorphisms in the genetic variations of vitamin K epoxide reductase complex subunit 1 (VKORC1) and Cytochrome P450 subfamily IIC polypeptide 9 (CYP2C9) have been shown to cause variability in anticoagulant response across various ethnic groups. In the Mestizo-Mexican population, with their Amerindian-European and African-Asiatic ancestral origins, the response is expected to differ as well. This study aims to evaluate the anticoagulant response to coumarin in Mestizo-Mexican patients with mechanical heart valve prostheses.
Method: DNA was extracted from blood samples using a commercial genomic DNA purification kit. The polymorphisms rs1799853 CT in the CYP2C9*2 gene and rs9923231VKORC1-G1639A gene were determined using real-time PCR. All patients initially received a dose of 8 mg/day of coumarin, which was adjusted on the second day based on international normalized ratio (INR) levels until reaching a result of 2.5-3.5.
Results : Seventy-six patients with an average age of 58±11 years were undergoing mitral (n=44) and aortic (n=32) valve replacement. Patients carrying GG haplotypes in the rs9923231VKORC1-G1639A gene variant required a significantly higher coumarin dose to reach the therapeutic range compared to those with GA and AA haplotypes (p=0.001). The rs1799853 polymorphism of the CYP2C9*2 A/C gene showed no significant differences between AA, AC, and CC haplotypes (p>0.05).
Conclusion : In the Mestizo-Mexican population, individuals carrying the rs9923231 VKORC1 gene with GG haplotypes exhibited a hyporeactive anticoagulant response compared to those with GA and AA haplotypes, which showed normal and hyperreactive responses, respectively. There were no significant differences in the response of the CYP2C9*2 haplotypes AC carriers.

Keywords

References

  1. Jamieson WE, Moffatt-Bruce SD, Skarsgard P, Hadi MA, Ye J, Fradet GJ, et al. Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use?. The Annals of thoracic surgery. 2007 Feb 1;83(2):549-57.
  2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014 Jun 10;63(22):e57-185.
  3.  Vahanian A, Alfieri O, Andreotti F. ESC/EACTS Guidelines on the management of valvular heart disease. Eur Heart J. 2012;33:2451-96.
  4. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 Jan 1;119(1):8S-21S.
  5. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. 2002 Apr 3;287(13):1690-8.
  6. Yuan HY, Chen JJ, Lee MM, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human molecular genetics. 2005 Jul 1;14(13):1745-51.
  7. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41.
  8. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thrombosis and haemostasis. 2005;93(01):23-6.
  9. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 Jan 15;105(2):645-9.
  10.  Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Polish Heart Journal (Kardiologia Polska). 2018;76(1):1-62.
  11. Zhang S, Zhao M, Zhong S, Niu J, Zhou L, Zhu B, et al. Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients. Pharmacogenetics and Genomics. 2024 Jun 1;34(4):105-16.
  12. Lezhava T, Kakauridze N, Jokhadze T, Buadze T, Gaiozishvili M, Gargulia K, et al. FREQUENCY OF VKORC1 AND CYP2C9 GENES POLYMORPHISM IN ABKHAZIAN POPULATION. Georgian Medical News. 2023 May 1(338):96-101.
  13.  Benavides F, Grossman N, Poggi H, Nieto E, Bertrán A, Araos D, et al. Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos. Revista médica de Chile. 2015 Nov;143(11):1369-76.
  14.  Castelán-Martínez OD, Hoyo-Vadillo C, Sandoval-García E, Sandoval-Ramírez L, González-Ibarra M, Solano-Solano G, et al. Allele frequency distribution of CYP2C9* 2 and CYP2C9* 3 polymorphisms in six Mexican populations. Gene. 2013 Jul 10;523(2):167-72.
  15. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-40.
  16.  Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Sai Chandran BV, Balachander J, et al. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. European journal of clinical pharmacology. 2015 Feb;71(2):173-81.
  17. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008 Feb 1;9(2):169-78.
  18. Topkara VK, Levin A, Mody K, Garan A, Ronquillo KO, Tiburcio M, et al. Association of Warfarin Genotype with Thrombosis and Bleeding Events in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients. The Journal of Heart and Lung Transplantation. 2015 Apr 1;34(4):S13.
  19. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Human genetics. 2007 Mar;121(1):23-34.
  20. Al-Eitan LN, Almasri AY, Alnaamneh AH, Aman HA, Alrabadi NN, Khasawneh RH, et al. Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan. International journal of medical sciences. 2021 Jan 1;18(3):826.
Journal of Cardio-Thoracic Medicine
Volume 14, Issue 1
March 2026
Pages 1662-1667

Files

Share

How to cite

Statistics